---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-044734"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2026-11-18T21:15:33+00:00"
generated_at: "2026-11-18T21:17:13.115714+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.62
calibrated_materiality_score: 0.62
confidence: "high"
source: SEC EDGAR
---

# Passage Bio gets Nasdaq deficiency notice; stockholders' equity $50K vs $2.5M minimum

## Summary
- Nasdaq Rule 5550(b)(1) requires $2.5M minimum stockholders' equity; Passage Bio reported $50,000 at Sept 30, 2026 and fails the market-value and net-income alternatives.
- Letter from Nasdaq Listing Qualifications dated Nov 12, 2026 has no immediate effect; PASG continues trading on the Nasdaq Capital Market.
- Company expects the pending Remix Therapeutics mergers (A&R agreement dated Sept 2, 2026, amended Oct 5, 2026) to restore compliance on close.
- Upon closing, Passage Bio will rename itself Remix Therapeutics, Inc. and trade under symbol RMTX; Nasdaq listing approval is a remaining closing condition.
- If the mergers are not completed within the Nasdaq-provided period, the company intends to submit a plan to regain compliance.

## SEC filing metadata
- accession: 0001140361-26-044734
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2026-11-18T21:15:33+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.62
- calibrated_materiality_score: 0.62
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000114036126044734/0001140361-26-044734-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000114036126044734/ef20085890_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-044734
- JSON: https://secwatch.observer/filing/0001140361-26-044734.json
- Plain text: https://secwatch.observer/filing/0001140361-26-044734.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.
